Effectiveness of blood pressure-lowering drug treatment by levels of absolute risk: post hoc analysis of the Australian National Blood Pressure Study

被引:11
|
作者
Ho, Chau Le Bao [1 ]
Breslin, Monique [1 ]
Doust, Jenny [2 ]
Reid, Christopher M. [3 ,4 ]
Nelson, Mark R. [1 ,4 ]
机构
[1] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia
[2] Bond Univ, Fac Hlth Sci & Med, Gold Coast, Qld, Australia
[3] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia
[4] Monash Univ, Sch Publ Hlth & Prevent Med, CCRE Therapeut, Melbourne, Vic, Australia
来源
BMJ OPEN | 2018年 / 8卷 / 03期
基金
英国医学研究理事会;
关键词
CARDIOVASCULAR-DISEASE RISK; SERUM-LIPIDS; HYPERTENSION; GUIDELINES; MANAGEMENT;
D O I
10.1136/bmjopen-2017-017723
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives In many current guidelines, blood pressure (BP)-lowering drug treatment for primary prevention of cardiovascular disease (CVD) is based on absolute risk. However, in clinical practice, therapeutic decisions are often based on BP levels alone. We sought to investigate which approach was superior by conducting a post hoc analysis of the Australian National Blood Pressure (ANBP) cohort, a seminal study establishing the efficacy of BP lowering in 'mild hypertensive' persons. Design A post hoc subgroup analysis of the ANBP trial results by baseline absolute risk tertile. Setting and participants 3244 participants aged 35-69 years in a community-based randomised placebo controlled trial of blood pressure-lowering medication. Interventions Chlorothiazide500 mg versus placebo. Primary outcome measures All-cause mortality and nonfatal events (non-fatal CUD, congestive cardiac failure, renal failure, hypertensive retinopathy or encephalopathy). Results Treatment effects were assessed by HR, absolute risk reduction and number needed to treat. Participants had an average 5-year CVD risk in the intermediate range (10.5 6.5) with moderately elevated BP (mean 159/103 mmHg) and were middle aged (52 8 years). In a subgroup analysis, the relative effects (HR) and absolute effects (absolute risk reduction and number needed to treat) did not statistically differ across the three risk groups except for the absolute benefit in all-cause mortality (p for heterogeneity=0.04). With respect to absolute benefit, drug treatment significantly reduced the number of events in the high-risk group regarding any event with a number needed to treat of 18 (10 to 64), death from any cause with 45 (25 to 196) and major CVD events with 23 (12 to 193). Conclusion Our analysis confirms that the benefit of treatment was substantial only in the high-risk tertile, reaffirming the rationale of treating elevated blood pressure in the setting of all risk factors rather than in isolation.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] POST HOC ANALYSIS OF THE EFFECTIVENESS OF BLOOD PRESSURE-LOWERING DRUG TREATMENT BY LEVELS OF ABSOLUTE RISK IN THE ANBP STUDY
    Ho, C. L. B.
    Breslin, M.
    Doust, J.
    Reid, C. M.
    Nelson, M. R.
    [J]. HYPERTENSION, 2017, 69 (06) : E26 - E26
  • [2] Effectiveness of blood pressure-lowering treatment by the levels of baseline Framingham risk score: A post hoc analysis of the Systolic Blood Pressure Intervention Trial (SPRINT)
    Zhang, Ling
    Sun, Xiuting
    Liao, Lizhen
    Zhang, Shaozhao
    Zhou, Huimin
    Zhong, Xiangbin
    Zhuang, Xiaodong
    Liao, Xinxue
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2019, 21 (12): : 1813 - 1820
  • [3] Residual Cardiovascular Risk in Individuals on Blood Pressure-Lowering Treatment
    Lieb, Wolfgang
    Enserro, Danielle M.
    Sullivan, Lisa M.
    Vasan, Ramachandran S.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (11):
  • [4] Gender and the response to blood pressure-lowering treatment
    Lip, Gregory Y. H.
    Butt, Mehmood
    [J]. EUROPEAN HEART JOURNAL, 2008, 29 (21) : 2585 - 2586
  • [5] Blood Pressure-Lowering Treatment Should Be Offered to All Patients Regardless of Blood Pressure
    McManus, Richard J.
    Mant, Jonathan
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2009, 11 (12): : 698 - 701
  • [6] Secondary prevention of stroke by blood pressure-lowering treatment
    Hisatomi Arima
    John Chalmers
    [J]. Current Hypertension Reports, 2006, 8 : 317 - 323
  • [7] Blood pressure-lowering treatment in acute intracerebral haemorrhage
    Berge, Eivind
    [J]. JOURNAL OF HYPERTENSION, 2015, 33 (05) : 931 - 932
  • [8] BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE TREATMENT AND INCIDENT DIABETES
    Nazarzadeh, Milad
    Bidel, Zeinab
    Canoy, Dexter
    Copland, Emma
    Wamil, Malgorzata
    Byrne, Karl Smith
    Sundstrom, Johan
    Teo, Koon
    Davis, Barry R.
    Chalmers, John
    Pepine, Carl J.
    Dehghan, Abbas
    Bennet, Derrick A.
    Smith, George Davey
    Rahimi, Kazem
    [J]. JOURNAL OF HYPERTENSION, 2021, 39 : E8 - E9
  • [9] Secondary prevention of stroke by blood pressure-lowering treatment
    Arima, Hisatomi
    Chalmers, John
    [J]. CURRENT HYPERTENSION REPORTS, 2006, 8 (04) : 317 - 323
  • [10] Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data
    Karmali, Kunal N.
    Lloyd-Jones, Donald M.
    van der Leeuw, Joep
    Goff, David C., Jr.
    Yusuf, Salim
    Zanchetti, Alberto
    Glasziou, Paul
    Jackson, Rodney
    Woodward, Mark
    Rodgers, Anthony
    Neal, Bruce C.
    Berge, Eivind
    Teo, Koon
    Davis, Barry R.
    Chalmers, John
    Pepine, Carl
    Rahimi, Kazem
    Sundstrom, Johan
    [J]. PLOS MEDICINE, 2018, 15 (03)